Literature DB >> 32198206

Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes.

Iuliia Polina1, Hailey J Jansen1,2,3, Tiesong Li1, Motahareh Moghtadaei1,2,3, Loryn J Bohne2,3, Yingjie Liu2,3, Pooja Krishnaswamy1, Emmanuel E Egom1, Darrell D Belke2,3, Sara A Rafferty1, Martin Ezeani1, Anne M Gillis2,3, Robert A Rose4,2,3.   

Abstract

Atrial fibrillation (AF) is prevalent in diabetes mellitus (DM); however, the basis for this is unknown. This study investigated AF susceptibility and atrial electrophysiology in type 1 diabetic Akita mice using in vivo intracardiac electrophysiology, high-resolution optical mapping in atrial preparations, and patch clamping in isolated atrial myocytes. qPCR and western blotting were used to assess ion channel expression. Akita mice were highly susceptible to AF in association with increased P-wave duration and slowed atrial conduction velocity. In a second model of type 1 DM, mice treated with streptozotocin (STZ) showed a similar increase in susceptibility to AF. Chronic insulin treatment reduced susceptibility and duration of AF and shortened P-wave duration in Akita mice. Atrial action potential (AP) morphology was altered in Akita mice due to a reduction in upstroke velocity and increases in AP duration. In Akita mice, atrial Na+ current (INa) and repolarizing K+ current (IK) carried by voltage gated K+ (Kv1.5) channels were reduced. The reduction in INa occurred in association with reduced expression of SCN5a and voltage gated Na+ (NaV1.5) channels as well as a shift in INa activation kinetics. Insulin potently and selectively increased INa in Akita mice without affecting IK Chronic insulin treatment increased INa in association with increased expression of NaV1.5. Acute insulin also increased INa, although to a smaller extent, due to enhanced insulin signaling via phosphatidylinositol 3,4,5-triphosphate (PIP3). Our study reveals a critical, selective role for insulin in regulating atrial INa, which impacts susceptibility to AF in type 1 DM.

Entities:  

Keywords:  Na+ current; action potential; atrial fibrillation; diabetes mellitus; phosphoinositide 3-kinase

Year:  2020        PMID: 32198206      PMCID: PMC7148583          DOI: 10.1073/pnas.1914853117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  63 in total

Review 1.  Molecular physiology of cardiac repolarization.

Authors:  Jeanne M Nerbonne; Robert S Kass
Journal:  Physiol Rev       Date:  2005-10       Impact factor: 37.312

2.  Atrial fibrillation and sinus node dysfunction in human ankyrin-B syndrome: a computational analysis.

Authors:  Roseanne M Wolf; Patric Glynn; Seyed Hashemi; Keyan Zarei; Colleen C Mitchell; Mark E Anderson; Peter J Mohler; Thomas J Hund
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-02-22       Impact factor: 4.733

Review 3.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Circulation       Date:  2014-08-11       Impact factor: 29.690

4.  Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure.

Authors:  Kai-Chien Yang; Patrick Y Jay; Julie R McMullen; Jeanne M Nerbonne
Journal:  Cardiovasc Res       Date:  2011-10-27       Impact factor: 10.787

5.  Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.

Authors:  Takeshi Kato; Takeshi Yamashita; Akiko Sekiguchi; Takayuki Tsuneda; Kouichi Sagara; Masayuki Takamura; Shuichi Kaneko; Tadanori Aizawa; Long-Tai Fu
Journal:  J Cardiol       Date:  2011-07-30       Impact factor: 3.159

6.  Diabetes mellitus, glycemic control, and risk of atrial fibrillation.

Authors:  Sascha Dublin; Nicole L Glazer; Nicholas L Smith; Bruce M Psaty; Thomas Lumley; Kerri L Wiggins; Richard L Page; Susan R Heckbert
Journal:  J Gen Intern Med       Date:  2010-04-20       Impact factor: 5.128

Review 7.  Atrial electrophysiology and mechanisms of atrial fibrillation.

Authors:  Stanley Nattel
Journal:  J Cardiovasc Pharmacol Ther       Date:  2003-06       Impact factor: 2.457

8.  Conduction and refractory disorders in the diabetic atrium.

Authors:  Masaya Watanabe; Hisashi Yokoshiki; Hirofumi Mitsuyama; Kazuya Mizukami; Taisuke Ono; Hiroyuki Tsutsui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-04       Impact factor: 4.733

9.  A Machine Learning Aided Systematic Review and Meta-Analysis of the Relative Risk of Atrial Fibrillation in Patients With Diabetes Mellitus.

Authors:  Zhaohan Xiong; Tong Liu; Gary Tse; Mengqi Gong; Patrick A Gladding; Bruce H Smaill; Martin K Stiles; Anne M Gillis; Jichao Zhao
Journal:  Front Physiol       Date:  2018-07-03       Impact factor: 4.566

Review 10.  Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus.

Authors:  Yubi Lin; Hairui Li; Xianwu Lan; Xianghui Chen; Aidong Zhang; Zicheng Li
Journal:  ScientificWorldJournal       Date:  2013-03-14
View more
  12 in total

1.  Hyperglycemia regulates cardiac K+ channels via O-GlcNAc-CaMKII and NOX2-ROS-PKC pathways.

Authors:  Bence Hegyi; Johanna M Borst; Logan R J Bailey; Erin Y Shen; Austen J Lucena; Manuel F Navedo; Julie Bossuyt; Donald M Bers
Journal:  Basic Res Cardiol       Date:  2020-11-25       Impact factor: 17.165

Review 2.  PI3K(p110α) as a determinant and gene therapy for atrial enlargement in atrial fibrillation.

Authors:  Martin Ezeani; Sandeep Prabhu
Journal:  Mol Cell Biochem       Date:  2022-07-28       Impact factor: 3.842

Review 3.  Mechanisms of Chronic Metabolic Stress in Arrhythmias.

Authors:  Blake H Gowen; Michael V Reyes; Leroy C Joseph; John P Morrow
Journal:  Antioxidants (Basel)       Date:  2020-10-19

4.  Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycaemia: reduced repolarization reserve, neurohormonal stimulation, and heart failure exacerbate susceptibility.

Authors:  Bence Hegyi; Christopher Y Ko; Julie Bossuyt; Donald M Bers
Journal:  Cardiovasc Res       Date:  2021-12-17       Impact factor: 13.081

5.  Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis.

Authors:  Arnaud Bisson; Alexandre Bodin; Grégoire Fauchier; Julien Herbert; Denis Angoulvant; Pierre Henri Ducluzeau; Gregory Y H Lip; Laurent Fauchier
Journal:  Cardiovasc Diabetol       Date:  2021-01-22       Impact factor: 9.951

Review 6.  Atrial Cardiomyopathy: Pathophysiology and Clinical Consequences.

Authors:  Andreas Goette; Uwe Lendeckel
Journal:  Cells       Date:  2021-09-30       Impact factor: 6.600

Review 7.  Structural and Electrical Remodeling of the Sinoatrial Node in Diabetes: New Dimensions and Perspectives.

Authors:  Lina T Al Kury; Stephanie Chacar; Eman Alefishat; Ali A Khraibi; Moni Nader
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-07       Impact factor: 6.055

8.  Impaired regulation of heart rate and sinoatrial node function by the parasympathetic nervous system in type 2 diabetic mice.

Authors:  Yingjie Liu; Hailey J Jansen; Pooja S Krishnaswamy; Oleg Bogachev; Robert A Rose
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

Review 9.  New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation.

Authors:  Martin Aguilar; Robert A Rose; Abhijit Takawale; Stanley Nattel; Svetlana Reilly
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787

10.  Necroptosis is required for atrial fibrillation and involved in aerobic exercise-conferred cardioprotection.

Authors:  Yuping Fu; Tiannan Jiang; Hongke Sun; Tong Li; Feng Gao; Boyuan Fan; Xiaoli Li; Xinghua Qin; Qiangsun Zheng
Journal:  J Cell Mol Med       Date:  2021-07-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.